Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis

Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes progressive joint damage. The Janus kinase (JAK) inhibitors (JAK-I) represent a new therapeutic option for RA patients, blocking the intracellular JAK-STAT pathway. Today, no studies have been conducted to determine w...

Full description

Bibliographic Details
Main Authors:	Maurizio Benucci, Francesca Li Gobbi, Paola Fusi, Arianna Damiani, Edda Russo, Serena Guiducci, Mariangela Manfredi, Valentina Grossi, Maria Infantino, Amedeo Amedei
Format:	Article
Language:	English
Published:	IMR Press 2023-08-01
Series:	Frontiers in Bioscience-Landmark
Subjects:	rheumatoid arthritis jak inhibitors upadacitinib filgotinib biomarkers
Online Access:	https://www.imrpress.com/journal/FBL/28/8/10.31083/j.fbl2808176

Similar Items

Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
by: Maurizio Benucci, et al.
Published: (2022-09-01)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019-10-01)

Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-<i>i</i> Study)
by: Maurizio Benucci, et al.
Published: (2024-03-01)

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment
by: Hiroshi Nakase
Published: (2023-07-01)

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice
by: Maurizio Benucci, et al.
Published: (2023-08-01)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2020-11-01)

The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective
by: Maurizio Benucci, et al.
Published: (2022-12-01)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
by: Toshimasa Shimizu, et al.
Published: (2023-03-01)

Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future
by: Navarini L, et al.
Published: (2020-11-01)

Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family
by: Amir Taldaev, et al.
Published: (2021-12-01)

JAK ACADEMY in Rheumatoid Arthritis (RA)
by: Roberto Caporali, et al.
Published: (2018-09-01)

Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
by: Christina Charles-Schoeman, et al.
Published: (2024-01-01)

Are the goals of therapy achievable in patients with rheumatoid arthritis receiving upadacitinib in real clinical practice?
by: V. N. Amirjanova, et al.
Published: (2022-07-01)

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis
by: Samantha Sarabia, et al.
Published: (2022-09-01)

JAK inhibitors in lichen planus: a review of pathogenesis and treatments
by: Ali Motamed-Sanaye, et al.
Published: (2022-11-01)

Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
by: Kinga Kołcz, et al.
Published: (2023-01-01)

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
by: Yoshiya Tanaka, et al.
Published: (2023-09-01)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020-11-01)

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
by: Martin Bergman, et al.
Published: (2022-06-01)

Efficacy and Safety of Upadacitinib in Rheumatoid Arthritis: Real-Life Experience from a Prospective Longitudinal Multicentric Study
by: Caterina Baldi, et al.
Published: (2024-01-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
by: Krzysztof Szalus, et al.
Published: (2020-11-01)

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes
by: Nina Yao, et al.
Published: (2021-10-01)

Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
by: He X, et al.
Published: (2024-03-01)

The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)
by: V. N. Amirjanova, et al.
Published: (2021-10-01)

Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study
by: Vincenzo Venerito, et al.
Published: (2023-01-01)

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases
by: Felis-Giemza A, et al.
Published: (2023-09-01)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
by: Vibeke Strand, et al.
Published: (2019-12-01)

JAK inhibitors for the treatment of rheumatoid arthritis
by: Akio Morinobu
Published: (2020-10-01)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
by: Hideto Kameda, et al.
Published: (2021-01-01)

Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials
by: Nie Liu-yan, et al.
Published: (2023-06-01)

Upadacitinib in nail psoriasis: a case report
by: Na Wang, et al.
Published: (2023-12-01)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
by: David Nash, BHSc, et al.
Published: (2023-02-01)

Use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases: safety issues
by: B. S. Belov, et al.
Published: (2021-03-01)

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
by: Maurizio Benucci, et al.
Published: (2022-07-01)

Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1174
by: Maurizio Benucci, et al.
Published: (2023-01-01)

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
by: Raimon Sanmartí, et al.
Published: (2023-02-01)